Oncogenic activation of tyrosine kinases

https://doi.org/10.1016/0959-437X(94)90086-8Get rights and content

Abstract

Tyrosine kinases comprise the largest group of oncoproteins, a fact that underscores the importance of reversible tyrosine phosphorylation in the regulation of essential cellular functions. Oncogenic activation of tyrosine kinases results in the constitutive activation of what is normally a conditionally regulated enzyme activity. Studies of tyrosine kinase oncoproteins, and a comparison with their corresponding proto-oncogene products, have identified important functional and regulatory domains within these proteins, positive and negative regulators of their enzyme activities and signalling cascades that control cell growth and differentiation.

References (94)

  • P.K. Jackson et al.

    Mutation of a Phenylalanine Conserved in SH3-Containing Tyrosine Kinascs Activates the Transforming Ability of c-Abl

    Oncogene

    (1993)
  • P. Cicchetti et al.

    Identification of a Protein that Binds to the SH3 Region of Abl and is Similar to Bcr and GAP-rho

    Science

    (1992)
  • J.B. Bolen

    Nonreccptor Tyrosine Protein Kinases

    Oncogene

    (1993)
  • S.A. Aaronson

    Growth Factors and Cancer

    Science

    (1991)
  • S. Rong et al.

    Tumorigenicity of the met Proto-Oncogene and the Gene for Hepatocyte Growth Factor

    Mol Cell Biol

    (1992)
  • M.J. Hayman et al.

    Cell Transformation by the Epidermal Growth Factor Receptor and v-erbB

    Cancer Cells

    (1991)
  • H.-K.G. Shu et al.

    Tissue-Specific Transformation by Epidermal Growth Factor Receptor. a Single Point Mutation within the ATP Binding Pocket of the erbB Product Increases its Intrinsic Kinasc Activity and Activates its Sarcomagenic Potential

  • H.K. Shu et al.

    Dissecting the Activating Mutations in v-erbB of Avian Erythroblastosis Virus Strain R

    Virology

    (1991)
  • E.B. Lee et al.

    Muational Analysis of the Role of the Carboxy-Terminal Region of the v-erbB Protein in Erythroid Cell Transformation

    Oncogene

    (1993)
  • H.L. Robinson et al.

    Characterization of an Angiosarcoma-Inducing Mutation in the erbB Oncogene

    Oncogene

    (1992)
  • C.S. Zong et al.

    Molecular and Biochemical Bases for Activation of the Transforming Potential of the Proto-Oncogene c-ros

    J Virology

    (1993)
  • M.F. Roussel et al.

    Transforming Activities of Human CSF-I Receptors with Different Point Mutations at Codon 301 in their Extracellular Domains

    Oncogene

    (1990)
  • T.V.D. Wetters et al.

    Random Mutagenesis of CSF-1 Receptor (FMS) Reveals Multiple Sites for Activating Mutations within the Extracellular Domain

    EMBO J

    (1992)
  • S. Mossoglia et al.

    Epidermal Growth Factor Receptor Cytoplasmic Domain Mutations Trigger Lignad-Independent Transformation

    Mol Cell Biol

    (1990)
  • P.P. Di Fiore et al.

    A Single Amino Acid Substitution is Sufficient to Modify the Mitogenic Properties of the Epidermal Growth Factor Receptor to Resemble that of gp185erbB-2

    EMBO J

    (1992)
  • D.B. Weiner et al.

    A Point Mutation in the neu Oncogene Mimics Ligand Induction of Receptor Aggregation

    Nature

    (1989)
  • C.I. Bargmann et al.

    Oncogenic Activation of the neu-Encoded Receptor, by a Point Mutation and Deletion

    EMBO J

    (1988)
  • R. Ben-Levy et al.

    An Oncogenic Point Mutation Confers High Affinity Lig and Binding to the neu Receptor

    J Biol Cbem

    (1993)
  • B. Cheatham et al.

    Substitution of the erbB-2 Oncoprotein Transmembrane Domain Activates the Insulin Receptor and Modulates the Action of Insulin and Insulin-Receptor Substrate 1

  • K. Yamada et al.

    Substitution of the Insulin Receptor Transmembrane Domain with the c-neu/erbB2 Transmembrane Domain Constitutively Ac tivates the Insulin Receptor Kinase in Who

    J Biol Chem

    (1992)
  • D. Martin-Zanca et al.

    A Human Oncogene Formed by the Fusion of Truncated Tropomyosin and Protein Tyrosine Kinase Sequences

    Nature

    (1986)
  • M. Park et al.

    Mechanism of met Oncogene Activation

    Cell

    (1986)
  • M. Takahashi et al.

    Activation of a Novel Human Transforming Gene, ret, by DNA Rearrangement

    Cell

    (1985)
  • Y. Ishizaka et al.

    Detection of Phosphorylated retTPC Oncogene Product in Cytoplasm

    Oncogene

    (1992)
  • G. Rodrigues et al.

    Dimerization Mediated by a Leucinc Zipper Oncogenically Activates the met Receptor Tyrosine Kinase

    Mol Cell Biol

    (1993)
  • A. Greco et al.

    Trk-tl is a Novel Oncogene Formed by the Fusion of tpr and trk Genes in a Human Papillary Thyroid Carcinoma

    Oncogene

    (1992)
  • S.C. Kozma et al.

    Activation of the Receptor Kinase Domain of the trk Oncogene by Recombination with Two Different Cellular Sequences

    EMBO J

    (1988)
  • I. Bongarzone et al.

    Molecular Characterization of a Thyroid Tumor-Specific Transforming Sequence Formed by the Fusion of ret Tyrosine Kinase and the Regulatory Subunit Rla of Cyclic AMP-dependent Protein Kinase A

    Mol Ceil Biol

    (1993)
  • C. Lanzi et al.

    Identification of the Product of Two Oncogenis Rearranged Forms of the RET Proto-Oncogene in Papillary Thyroid Carcinomas

    Oncogene

    (1992)
  • A.J. Crowe et al.

    Post-Translational Modifications of the env-sea Oncogene Product: the Role of Proteolytic Processing in Transformation

    Oncogene

    (1993)
  • J.R. Feramisco et al.

    Transient Reversion of ras Oncogene-Induced Cell Transformation by Antibodies Specific for Amino Acid 12 of ras Protein

    Nature

    (1985)
  • G. Sozzi et al.

    Cytogenic and Molecular Genetic Characterization of Papil iary Thyroid Carcinomas

    Genes Chromosomes Cancer

    (1992)
  • M.A. Pierotti et al.

    Characterization of an Inversion on the Long Arm of Chromosome 10 Juxtaposing DIOS170 and REf and Creating the Oncogenic Sequence REt/PTC

  • J.T. Parsons et al.

    Genetics of src: Structure and Functional Organization of a Protein Tyrosine Kinase

    Curr Top Microbiol Immunol

    (1989)
  • C.A. Koch et al.

    SH2 and SH3 Domains: Elements that Control Interactions of Cytoplasmic Signaling Proteins

    Science

    (1991)
  • M. Matsuda et al.

    Binding of Transforming Protein, P47gag-crk, to a Broad Range of Phosphotyrosine-Containing Proteins

    Science

    (1990)
  • J.A. Cooper et al.

    The When and How of Src Regulation

    Cell

    (1993)
  • Cited by (123)

    • (-)-Epigallocatechin gallate regulates CD3-mediated T cell receptor signaling in leukemia through the inhibition of ZAP-70 kinase

      2008, Journal of Biological Chemistry
      Citation Excerpt :

      Tyrosine kinases include the largest group of oncoproteins (47). The recent development of a series of relatively specific protein-tyrosine kinase (PTK) inhibitors with the ability to suppress the proliferation of tumor cells expressing the target PTK in vivo shows that inhibition of deregulated, dominant oncogenic PTKs is often enough to slow tumor progression (48). Research results suggest that targeted molecular cancer therapies can potentially deliver treatment directly to a specific protein or gene target and optimize efficacy and thus reduce adverse side effects often associated with traditional chemotherapy.

    View all citing articles on Scopus

    present address, Dept of Pharmacology, New York University Medical Center, 550 First Avenue, New York, New York 10016, cyUSA.

    View full text